Search

Your search keyword '"Rodinò, Stefano"' showing total 42 results
Start Over Author "Rodinò, Stefano"
42 results on '"Rodinò, Stefano"'

1. Examples of a Learning-By-Doing Approach for Bachelor and Master Students Approaching Robot Design

Author

Curcio, Elio Matteo, Lago, Francesco, Rodino, Stefano, Carbone, Giuseppe, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, and Jauregui-Correa, Juan Carlos, editor

Published
2024
Full Text
View/download PDF

4. An Automatic Measurement System for Shape Memory Alloys’ Wire Resistivity Characterization

Author

Siciliano, Marco, Lamonaca, Francesco, Carnì, Domenico Luca, Rodinò, Stefano, Curcio, Elio Matteo, Carbone, Giuseppe, Mundo, Domenico, Maletta, Carmine, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, Petuya, Victor, editor, Quaglia, Giuseppe, editor, Parikyan, Tigran, editor, and Carbone, Giuseppe, editor

Published
2023
Full Text
View/download PDF

8. Modelling and Simulation of ADIUTOR Upper Limb Rehabilitation Robot

Author

Curcio, Elio M., Quacquarelli, Mariagrazia, Cariven, Léa L. H. I., Pitti, Estelle M. C., De Momi, Elena, Lago, Francesco, Rodino’, Stefano, Carbone, Giuseppe, Ceccarelli, Marco, Series Editor, Agrawal, Sunil K., Advisory Editor, Corves, Burkhard, Advisory Editor, Glazunov, Victor, Advisory Editor, Hernández, Alfonso, Advisory Editor, Huang, Tian, Advisory Editor, Jauregui Correa, Juan Carlos, Advisory Editor, Takeda, Yukio, Advisory Editor, Niola, Vincenzo, editor, Gasparetto, Alessandro, editor, Quaglia, Giuseppe, editor, and Carbone, Giuseppe, editor

Published
2022
Full Text
View/download PDF

10. Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey

Author

Massironi, Sara, Bianco, Maria Antonia, Germanà, Bastianello, Rodinò, Stefano, Anderloni, Andrea, Mussetto, Alessandro, Nipote, Bruno, Russo, Salvatore, Manta, Raffaele, Lauri, Adriano, Occhipinti, Vincenzo, Marco, Marco Di, Giovannone, Maurizio, Binda, Cecilia, Sbrancia, Monica, Paolo, Maria Carla Di, de’-Angelis, Gian Luigi, Fiori, Giancarla, Dal-Fante, Marco, Caro, Giuseppe de, Usai-Satta, Paolo, Cesarini, Monica, Piras, Enrico, Stasi, Elisa, Serio, Giovanni, Montalbano, Luigi Maria, Mirante, Vincenzo Giorgio, Burattini, Osvaldo, Attardo, Simona, Bargiggia, Stefano, Dinca, Manuele, Missale, Guido, Alvisi, Costanza, Broglia, Francesco, Ferraris, Luca, Conti-Bellocchi, Maria Cristina, Luigiano, Carmelo, Pallio, Socrate, Brunacci, Matteo, Manfrini, Carlo, Bozzi, Rosamaria, Checchin, Davide, Togliani, Thomas, D'errico, Antonietta, Bazzoli, Franco, La Bianca, Orazio, Berretti, Debora, Alvaro, Domenico, Buscarini, Elisabetta, Benedetti, Antonio, Monica, Fabio, Pasquale, Luigi, Buttitta, Francesco, Cameletti, Michela, Ferrari, Clarissa, and Ricciardiello, Luigi

Published
2021
Full Text
View/download PDF

12. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study

Author

Tursi, Antonio, Mocci, Giammarco, Scaldaferri, Franco, Napolitano, Daniele, Maresca, Rossella, Pugliese, Daniela, Semprucci, Gianluca, Savarino, Edoardo, Cuomo, Antonio, Donnarumma, Laura, Bodini, Giorgia, Pasta, Andrea, Maconi, Giovanni, Cataletti, Giovanni, Pranzo, Giuseppe, Rodinò, Stefano, Sebkova, Ladislava, Costa, Francesco, Ferronato, Antonio, Gaiani, Federica, Marzo, Manuela, Luppino, Ileana, Fabiano, Giulia, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Grossi, Laurino, Serio, Mariaelena, Scarcelli, Antonella, Lorenzetti, Roberto, Allegretta, Leonardo, Chiri, Stefania, Grasso, Giuseppina, Antonelli, Elisabetta, Bassotti, Gabrio, Spagnuolo, Rocco, Luzza, Francesco, Fanigliulo, Libera, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Rocchi, Chiara, Bolognini, Laura, Bendia, Emanuele, Bianco, Maria Antonia, Capone, Pietro, Meucci, Costantino, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Della Valle, Nicola, Felice, Carla, Pica, Roberta, Cocco, Andrea, Forti, Giacomo, Onidi, Francesca Maria, Usai Satta, Paolo, Checchin, Davide, Gravina, Antonietta Gerarda, Pellegrino, Raffaele, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Scaldaferri, Franco, Napolitano, Daniele, Maresca, Rossella, Pugliese, Daniela, Semprucci, Gianluca, Savarino, Edoardo, Cuomo, Antonio, Donnarumma, Laura, Bodini, Giorgia, Pasta, Andrea, Maconi, Giovanni, Cataletti, Giovanni, Pranzo, Giuseppe, Rodinò, Stefano, Sebkova, Ladislava, Costa, Francesco, Ferronato, Antonio, Gaiani, Federica, Marzo, Manuela, Luppino, Ileana, Fabiano, Giulia, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Grossi, Laurino, Serio, Mariaelena, Scarcelli, Antonella, Lorenzetti, Roberto, Allegretta, Leonardo, Chiri, Stefania, Grasso, Giuseppina, Antonelli, Elisabetta, Bassotti, Gabrio, Spagnuolo, Rocco, Luzza, Francesco, Fanigliulo, Libera, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Rocchi, Chiara, Bolognini, Laura, Bendia, Emanuele, Bianco, Maria Antonia, Capone, Pietro, Meucci, Costantino, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Della Valle, Nicola, Felice, Carla, Pica, Roberta, Cocco, Andrea, Forti, Giacomo, Onidi, Francesca Maria, Usai Satta, Paolo, Checchin, Davide, Gravina, Antonietta Gerarda, Pellegrino, Raffaele, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

BackgroundUstekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in patients with UC in a real-world setting.Research design and methodsThis is a multicenter, retrospective, observational cohort study. The primary endpoints were the clinical remission rate (partial Mayo score, PMS, <= 1) and the safety of UST. Other endpoints were corticosteroid-free remission (CSFR) rate, clinical response rate (PMS reduction of at least 2 points), and fecal calprotectin (FC) reduction at week 24.ResultsWe included 256 consecutive patients with UC (M/F 139/117, median age 52). The clinical remission and clinical response rates at eight weeks were 18.7% (44/235) and 53.2% (125/235), respectively, and 27.6% (42/152) and 61.8% (94/152) at 24 weeks, respectively. At 24 weeks, CSFR was 20.3% (31/152), and FC significantly dropped at week 12 (p = 0.0004) and 24 (p = 0.038). At eight weeks, patients naive or with one previous biologic treatment showed higher remission (p = 0.002) and clinical response rates (p = 0.018) than patients previously treated with >= 2. Adverse events occurred in six patients (2.3%), whereas four patients (1.6%) underwent colectomy.ConclusionThis real-world study shows that UST effectively and safely treats patients with UC.

Published
2024

13. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Scaldaferri, Franco, additional, Napolitano, Daniele, additional, Maresca, Rossella, additional, Pugliese, Daniela, additional, Semprucci, Gianluca, additional, Savarino, Edoardo, additional, Cuomo, Antonio, additional, Donnarumma, Laura, additional, Bodini, Giorgia, additional, Pasta, Andrea, additional, Maconi, Giovanni, additional, Cataletti, Giovanni, additional, Pranzo, Giuseppe, additional, Rodinò, Stefano, additional, Sebkova, Ladislava, additional, Costa, Francesco, additional, Ferronato, Antonio, additional, Gaiani, Federica, additional, Marzo, Manuela, additional, Luppino, Ileana, additional, Fabiano, Giulia, additional, Paese, Pietro, additional, Elisei, Walter, additional, Monterubbianesi, Rita, additional, Faggiani, Roberto, additional, Grossi, Laurino, additional, Serio, Mariaelena, additional, Scarcelli, Antonella, additional, Lorenzetti, Roberto, additional, Allegretta, Leonardo, additional, Chiri, Stefania, additional, Grasso, Giuseppina, additional, Antonelli, Elisabetta, additional, Bassotti, Gabrio, additional, Spagnuolo, Rocco, additional, Luzza, Francesco, additional, Fanigliulo, Libera, additional, Rocco, Giulia, additional, Sacchi, Carlotta, additional, Zampaletta, Costantino, additional, Rocchi, Chiara, additional, Bolognini, Laura, additional, Bendia, Emanuele, additional, Bianco, Maria Antonia, additional, Capone, Pietro, additional, Meucci, Costantino, additional, Colucci, Raffaele, additional, Tonti, Paolo, additional, Neve, Viviana, additional, Della Valle, Nicola, additional, Felice, Carla, additional, Pica, Roberta, additional, Cocco, Andrea, additional, Forti, Giacomo, additional, Onidi, Francesca Maria, additional, Usai Satta, Paolo, additional, Checchin, Davide, additional, Gravina, Antonietta Gerarda, additional, Pellegrino, Raffaele, additional, Picchio, Marcello, additional, and Papa, Alfredo, additional

Published
2024
Full Text
View/download PDF

14. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers

Author

Tursi, Antonio, Mocci, Giammarco, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Medici, Antonio de, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Grasso, Giuseppina, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Penna, Antonio, Rodino', Stefano, Sebkova, Ladislava, Lauria, Angelo, Piergallini, Simona, Pranzo, Giuseppe, Scorza, Stefano, Zampaletta, Costantino, Picchio, Marcello, and Elisei, Walter

Published
2019
Full Text
View/download PDF

15. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Cingolani, Linda, additional, Savarino, Edoardo, additional, Pica, Roberta, additional, Cocco, Andrea, additional, Zippi, Maddalena, additional, Napolitano, Daniele, additional, Schiavoni, Elisa, additional, Pugliese, Daniela, additional, Scaldaferri, Franco, additional, Costa, Francesco, additional, Marzo, Manuela, additional, Serio, Mariaelena, additional, Scarcelli, Antonella, additional, Bolognini, Laura, additional, Bendia, Emanuele, additional, Maconi, Giovanni, additional, Cannatelli, Rosanna, additional, Piergallini, Simona, additional, Bodini, Giorgia, additional, Calabrese, Francesco, additional, Ferronato, Antonio, additional, Pranzo, Giuseppe, additional, Elisei, Walter, additional, Monterubbianesi, Rita, additional, Faggiani, Roberto, additional, Rodinò, Stefano, additional, Sebkova, Ladislava, additional, Grossi, Laurino, additional, Gaiani, Federica, additional, dè Angelis, Gianluigi, additional, Lorenzetti, Roberto, additional, Allegretta, Leonardo, additional, Cazzato, Alessia Immacolata, additional, Scorza, Stefano, additional, Della Valle, Nicola, additional, Sacco, Rodolfo, additional, Forti, Giacomo, additional, Colucci, Raffaele, additional, Tonti, Paolo, additional, Neve, Viviana, additional, Rocco, Giulia, additional, Sacchi, Carlotta, additional, Zampaletta, Costantino, additional, Pagnini, Cristiano, additional, Graziani, Maria Giovanna, additional, Di Paolo, Maria Carla, additional, Onidi, Francesca Maria, additional, Usai Satta, Paolo, additional, Picchio, Marcello, additional, and Papa, Alfredo, additional

Published
2023
Full Text
View/download PDF

17. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Author

Tursi, Antonio, Mocci, Giammarco, Cingolani, Linda, Savarino, Edoardo, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Napolitano, Daniele, Schiavoni, Elisa, Pugliese, Daniela, Scaldaferri, Franco, Costa, Francesco, Marzo, Manuela, Serio, Mariaelena, Scarcelli, Antonella, Bolognini, Laura, Bendia, Emanuele, Maconi, Giovanni, Cannatelli, Rosanna, Piergallini, Simona, Bodini, Giorgia, Calabrese, Francesco, Ferronato, Antonio, Pranzo, Giuseppe, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Rodinò, Stefano, Sebkova, Ladislava, Grossi, Laurino, Gaiani, Federica, dè Angelis, Gianluigi, Lorenzetti, Roberto, Allegretta, Leonardo, Cazzato, Alessia Immacolata, Scorza, Stefano, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Onidi, Francesca Maria, Usai Satta, Paolo, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Cingolani, Linda, Savarino, Edoardo, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Napolitano, Daniele, Schiavoni, Elisa, Pugliese, Daniela, Scaldaferri, Franco, Costa, Francesco, Marzo, Manuela, Serio, Mariaelena, Scarcelli, Antonella, Bolognini, Laura, Bendia, Emanuele, Maconi, Giovanni, Cannatelli, Rosanna, Piergallini, Simona, Bodini, Giorgia, Calabrese, Francesco, Ferronato, Antonio, Pranzo, Giuseppe, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Rodinò, Stefano, Sebkova, Ladislava, Grossi, Laurino, Gaiani, Federica, dè Angelis, Gianluigi, Lorenzetti, Roberto, Allegretta, Leonardo, Cazzato, Alessia Immacolata, Scorza, Stefano, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Onidi, Francesca Maria, Usai Satta, Paolo, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

BackgroundData regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.Research design and methodsA retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of TOF.ResultsWe enrolled 166 patients with a median follow-up of 24 (IQR 8-36) weeks. Clinical remission was achieved in 61/166 (36.7%) and 75/166 (45.2%) patients at 8-week and 24-week follow-ups, respectively. The optimization was requested in 27 (16.3%) patients. Clinical remission was achieved more frequently when TOF was used as a first/second line rather than a third/fourth line treatment (p = 0.007). Mucosal healing was reported in 46% of patients at the median follow-up time. Colectomy occurred in 8 (4.8%) patients. Adverse events occurred in 12 (5.4%) patients and severe in 3 (1.8%). One case of simple Herpes Zoster and one of renal vein thrombosis were recorded.ConclusionsOur RW data confirm that TOF is effective and safe in UC patients. It performs remarkably better when used as the first/second line of treatment.

Published
2023

18. Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis

Author

Tursi, Antonio, Piovani, Daniele, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonia, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan L., Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Compare, Debora, Nardone, Gerardo, Camara De Castro Oliveira, Lucia, Oliveira, Enio Chave, Papa, Alfredo, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Poskus, Toma, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Spaziani, Erasmo, Bonovas, Stefano, Danese, Silvio, Null, Null, Papa, Alfredo (ORCID:0000-0002-4186-7298), Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Tursi, Antonio, Piovani, Daniele, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonia, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan L., Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Compare, Debora, Nardone, Gerardo, Camara De Castro Oliveira, Lucia, Oliveira, Enio Chave, Papa, Alfredo, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Poskus, Toma, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Spaziani, Erasmo, Bonovas, Stefano, Danese, Silvio, Null, Null, Papa, Alfredo (ORCID:0000-0002-4186-7298), and Scaldaferri, Franco (ORCID:0000-0001-8334-7541)

Abstract

Background and AimsThe Diverticular Inflammation and Complication Assessment (DICA) classification and the Combined Overview on Diverticular Assessment (CODA) were found to be effective in predicting the outcomes of Diverticular Disease (DD). We ascertain whether fecal calprotectin (FC) can further aid in improving risk stratification. MethodsA three-year international, multicentre, prospective cohort study was conducted involving 43 Gastroenterology and Endoscopy centres. Survival methods for censored observations were used to estimate the risk of acute diverticulitis (AD) in newly diagnosed DD patients according to basal FC, DICA, and CODA. The net benefit of management strategies based on DICA, CODA and FC in addition to CODA was assessed with decision curve analysis, which incorporates the harms and benefits of using a prognostic model for clinical decisions. ResultsAt the first diagnosis of diverticulosis/DD, 871 participants underwent FC measurement. FC was associated with the risk of AD at 3 years (HR per each base 10 logarithm increase: 3.29; 95% confidence interval, 2.13-5.10) and showed moderate discrimination (c-statistic: 0.685; 0.614-0.756). DICA and CODA were more accurate predictors of AD than FC. However, FC showed high discrimination capacity to predict AD at 3 months, which was not maintained at longer follow-up times. The decision curve analysis comparing the combination of FC and CODA with CODA alone did not clearly indicate a larger net benefit of one strategy over the other. ConclusionsFC measurement could be used as a complementary tool to assess the immediate risk of AD. In all other cases, treatment strategies based on the CODA score alone should be recommended.

Published
2023

19. Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis

Author

Tursi, Antonio, Piovani, Daniele, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonia, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan L., Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Compare, Debora, Nardone, Gerardo, Camara De Castro Oliveira, Lucia, Chaves Oliveira, Enio, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Stundiene, Ieva, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Spaziani, Erasmo, Bonovas, Stefano, Papa, Alfredo, Danese, Silvio, Null, Null, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Piovani, Daniele, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonia, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan L., Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Compare, Debora, Nardone, Gerardo, Camara De Castro Oliveira, Lucia, Chaves Oliveira, Enio, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Stundiene, Ieva, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Spaziani, Erasmo, Bonovas, Stefano, Papa, Alfredo, Danese, Silvio, Null, Null, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

INTRODUCTION: We assessed the prevalence and clinical outcomes of segmental colitis associated with diverticulosis (SCAD) in patients with newly diagnosed diverticulosis.METHODS: A 3-year international, multicenter, prospective cohort study was conducted involving 2,215 patients.RESULTS: SCAD diagnosis was posed in 44 patients (30 male patients; median age: 64.5 years; prevalence of 1.99%, 95% confidence interval, 1.45%-2.66%). Patients with SCAD types D and B showed worse symptoms, higher fecal calprotectin values, needed more steroids, and reached less likely complete remission.DISCUSSION: Although SCAD generally had a benign outcome, types B and D were associated with more severe symptoms and worse clinical course.[GRAPHICS].

Published
2023

21. Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study

Author

Tursi, Antonio, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonietta, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan, Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Nardone, Gerardo, Camara de Castro Oliveira, Lucia, Chaves Oliveira, Enio, Papa, Alfredo, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Poskus, Toma, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Piovani, Daniele, Bonovas, Stefano, Danese, Silvio, Papa, Alfredo (ORCID:0000-0002-4186-7298), Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Tursi, Antonio, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonietta, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan, Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Nardone, Gerardo, Camara de Castro Oliveira, Lucia, Chaves Oliveira, Enio, Papa, Alfredo, Papagrigoriadis, Savva, Pietrzak, Anna, Pontone, Stefano, Poskus, Toma, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Piovani, Daniele, Bonovas, Stefano, Danese, Silvio, Papa, Alfredo (ORCID:0000-0002-4186-7298), and Scaldaferri, Franco (ORCID:0000-0001-8334-7541)

Abstract

Objective To investigate the predictive value of the Diverticular Inflammation and Complication Assessment (DICA) classification and to develop and validate a combined endoscopic-clinical score predicting clinical outcomes of diverticulosis, named Combined Overview on Diverticular Assessment (CODA).Design A multicentre, prospective, international cohort study.Setting 43 gastroenterology and endoscopy centres located in Europe and South America.Participants 2215 patients (2198 completing the study) at the first diagnosis of diverticulosis/diverticular disease were enrolled. Patients were scored according to DICA classifications.Interventions A 3-year follow-up was performed.Main outcome measures To predict the acute diverticulitis and the surgery according to DICA classification. Survival methods for censored observation were used to develop and validate a novel combined endoscopic-clinical score for predicting diverticulitis and surgery (CODA score).Results The 3-year cumulative probability of diverticulitis and surgery was of 3.3% (95% CI 2.5% to 4.5%) in DICA 1, 11.6% (95% CI 9.2% to 14.5%) in DICA 2 and 22.0% (95% CI 17.2% to 28.0%) in DICA 3 (p<0.001), and 0.15% (95% CI 0.04% to 0.59%) in DICA 1, 3.0% (95% CI 1.9% to 4.7%) in DICA 2 and 11.0% (95% CI 7.5% to 16.0%) in DICA 3 (p<0.001), respectively. The 3-year cumulative probability of diverticulitis and surgery was <= 4%, and <= 0.7% in CODA A; 10% and >2.5% in CODA C, respectively. The CODA score showed optimal discrimination capacity in predicting the risk of surgery in the development (c-statistic: 0.829; 95% CI 0.811 to 0.846) and validation cohort (c-statistic: 0.943; 95% CI 0.905 to 0.981).Conclusions DICA classification has a significant role in predicting the risk of diverticulitis and surgery in patients with diverticulosis, which is significantly enhanced by the CODA score.

Published
2022

24. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Allegretta, Leonardo, additional, Aragona, Giovanni, additional, Bianco, Maria Antonia, additional, Colucci, Raffaele, additional, Cuomo, Antonio, additional, Della Valle, Nicola, additional, Ferronato, Antonio, additional, Forti, Giacomo, additional, Gaiani, Federica, additional, Graziani, Maria Giovanna, additional, Lorenzetti, Roberto, additional, Luzza, Francesco, additional, Paese, Pietro, additional, Penna, Antonio, additional, Pica, Roberta, additional, Pranzo, Giuseppe, additional, Rodinò, Stefano, additional, Scarcelli, Antonella, additional, Zampaletta, Costantino, additional, Brozzi, Lorenzo, additional, Cicerone, Clelia, additional, Cocco, Andrea, additional, De’ Angelis, Gianluigi, additional, Donnarumma, Laura, additional, Fiorella, Serafina, additional, Iannelli, Chiara, additional, Larussa, Tiziana, additional, Le Grazie, Marco, additional, Luppino, Ileana, additional, Meucci, Costantino, additional, FaggianI, Roberto, additional, Pagnini, Cristiano, additional, Perazzo, Patrizia, additional, Rodriguez-Castro, Kryssia Isabel, additional, Sacco, Rodolfo, additional, Sebkova, Ladislava, additional, Serio, Mariaelena, additional, De Monti, Alberta, additional, Picchio, Marcello, additional, Napolitano, Daniele, additional, Schiavoni, Elisa, additional, Turchini, Laura, additional, Scaldaferri, Franco, additional, Pugliese, Daniela, additional, Guidi, Luisa, additional, Laterza, Lucrezia, additional, Privitera, Giuseppe, additional, Pizzoferrato, Marco, additional, Lopetuso, Loris R., additional, Armuzzi, Alessandro, additional, Elisei, Walter, additional, Maconi, Giovanni, additional, and Papa, Alfredo, additional

Published
2021
Full Text
View/download PDF

25. Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab

Author

Tursi, Antonio, primary, Mocci, Giammarco, primary, Elisei, Walter, primary, Allegretta, Leonardo, primary, Colucci, Raffaele, primary, Della Valle, Nicola, primary, De Medici, Antonio, primary, Faggiani, Roberto, primary, Ferronato, Antonio, primary, Forti, Giacomo, primary, Larussa, Tiziana, primary, Lorenzetti, Roberto, primary, Luzza, Francesco, primary, Penna, Antonio, primary, Pranzo, Giuseppe, primary, Rodinò, Stefano, primary, Sacco, Rodolfo, primary, Sebkova, Ladislava, primary, Zampaletta, Costantino, primary, Graziosi, Camilla, primary, Picchio, Marcello, primary, Bergna, Irene Maria Bambina, primary, and Maconi, Giovanni, primary

Published
2021
Full Text
View/download PDF

26. Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study

Author

Tursi, Antonio, primary, Brandimarte, Giovanni, additional, Di Mario, Francesco, additional, Elisei, Walter, additional, Picchio, Marcello, additional, Allegretta, Leonardo, additional, Annunziata, Maria Laura, additional, Bafutto, Mauro, additional, Bassotti, Gabrio, additional, Bianco, Maria Antonietta, additional, Colucci, Raffaele, additional, Conigliaro, Rita, additional, Dumitrascu, Dan, additional, Escalante, Ricardo, additional, Ferrini, Luciano, additional, Forti, Giacomo, additional, Franceschi, Marilisa, additional, Graziani, Maria Giovanna, additional, Lammert, Frank, additional, Latella, Giovanni, additional, Maconi, Giovanni, additional, Nardone, Gerardo, additional, Camara de Castro Oliveira, Lucia, additional, Chaves Oliveira, Enio, additional, Papa, Alfredo, additional, Papagrigoriadis, Savvas, additional, Pietrzak, Anna, additional, Pontone, Stefano, additional, Poskus, Tomas, additional, Pranzo, Giuseppe, additional, Reichert, Matthias Christian, additional, Rodinò, Stefano, additional, Regula, Jaroslaw, additional, Scaccianoce, Giuseppe, additional, Scaldaferri, Franco, additional, Vassallo, Roberto, additional, Zampaletta, Costantino, additional, Zullo, Angelo, additional, Piovani, Daniele, additional, Bonovas, Stefanos, additional, and Danese, Silvio, additional

Published
2021
Full Text
View/download PDF

27. Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey

Author

Buscarini, Elisabetta, primary, Benedetti, Antonio, additional, Monica, Fabio, additional, Pasquale, Luigi, additional, Buttitta, Francesco, additional, Cameletti, Michela, additional, Ferrari, Clarissa, additional, Ricciardiello, Luigi, additional, Massironi, Sara, additional, Bianco, Maria Antonia, additional, Germanà, Bastianello, additional, Rodinò, Stefano, additional, Anderloni, Andrea, additional, Mussetto, Alessandro, additional, Nipote, Bruno, additional, Russo, Salvatore, additional, Manta, Raffaele, additional, Lauri, Adriano, additional, Occhipinti, Vincenzo, additional, Marco, Marco Di, additional, Giovannone, Maurizio, additional, Binda, Cecilia, additional, Sbrancia, Monica, additional, Paolo, Maria Carla Di, additional, de’-Angelis, Gian Luigi, additional, Fiori, Giancarla, additional, Dal-Fante, Marco, additional, Caro, Giuseppe de, additional, Usai-Satta, Paolo, additional, Cesarini, Monica, additional, Piras, Enrico, additional, Stasi, Elisa, additional, Serio, Giovanni, additional, Montalbano, Luigi Maria, additional, Mirante, Vincenzo Giorgio, additional, Burattini, Osvaldo, additional, Attardo, Simona, additional, Bargiggia, Stefano, additional, Dinca, Manuele, additional, Missale, Guido, additional, Alvisi, Costanza, additional, Broglia, Francesco, additional, Ferraris, Luca, additional, Conti-Bellocchi, Maria Cristina, additional, Luigiano, Carmelo, additional, Pallio, Socrate, additional, Brunacci, Matteo, additional, Manfrini, Carlo, additional, Bozzi, Rosamaria, additional, Checchin, Davide, additional, Togliani, Thomas, additional, D'errico, Antonietta, additional, Bazzoli, Franco, additional, La Bianca, Orazio, additional, Berretti, Debora, additional, and Alvaro, Domenico, additional

Published
2021
Full Text
View/download PDF

29. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy

Author

Roberti, Roberta, primary, Iannone, Luigi Francesco, additional, Palleria, Caterina, additional, De Sarro, Caterina, additional, Spagnuolo, Rocco, additional, Barbieri, Maria Antonietta, additional, Vero, Ada, additional, Manti, Antonia, additional, Pisana, Valentina, additional, Fries, Walter, additional, Trifirò, Gianluca, additional, Naturale, Maria Diana, additional, Larussa, Tiziana, additional, De Francesco, Adele Emanuela, additional, Bosco, Vincenzo, additional, Donato di Paola, Eugenio, additional, Citraro, Rita, additional, Luzza, Francesco, additional, Bennardo, Luigi, additional, Rodinò, Stefano, additional, Doldo, Patrizia, additional, Spina, Edoardo, additional, Russo, Emilio, additional, and De Sarro, Giovambattista, additional

Published
2020
Full Text
View/download PDF

30. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

Author

Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Graziani, Maria Giovanna, Lorenzetti, Roberto, Luzza, Francesco, Paese, Pietro, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodinò, Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Brozzi, Lorenzo, Cicerone, Clelia, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Fiorella, Serafina, Iannelli, Chiara, Larussa, Tiziana, Le Grazie, Marco, Luppino, Ileana, Meucci, Costantino, FaggianI, Roberto, Pagnini, Cristiano, Perazzo, Patrizia, Rodriguez-Castro, Kryssia Isabel, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, De Monti, Alberta, Picchio, Marcello, Napolitano, Daniele, Schiavoni, Elisa, Turchini, Laura, Scaldaferri, Franco, Pugliese, Daniela, Guidi, Luisa, Laterza, Lucrezia, Privitera, Giuseppe, Pizzoferrato, Marco, Lopetuso, Loris R., Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, and Papa, Alfredo

Abstract

ABSTRACTBackgroundTo compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.Research Design and MethodsThree hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.Results197 patients with Ulcerative Colitis (UC) and 183 patients with Crohn’s Disease (CD) treated with CT-P13 or SB2 and having a median (IQR) follow-up of 12 (6–36) months were compared: 230 (60.5%) were naïve to anti-TNFα, 20 (5.26%) were switched from IFX originator or from IFX CT-P13 to IFX SB2. Clinical remission was achieved in 133 (67.5%) UC patients and in 164 (89.6%) CD patients (p < 0.000), with no differences between CT-P13 and SB2 in the rate of remission in UC (p = 0.667) and CD (p = 0.286). Clinical response, steroid-free remission, rate of surgery, mucosal healing (MH) in UC, switching from IFX originator or from other biosimilar, and safety were similar. Higher MH rate was obtained in CD patients treated with CT-P13 (p = 0.004).ConclusionThis first comparative study found that both IFX biosimilars CT-P13 and SB2 are effective and safe in managing IBD outpatients.

Published
2022
Full Text
View/download PDF

31. Mo1867 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Author

Pugliese, Daniela, Privitera, Giuseppe, Crispino, Federica, Mezzina, Nicolò, Pellegrini, Lucienne, Laterza, Lucrezia, Viola, Anna, Soru, Pietro, Scrivo, Barbara, Barberio, Brigida, Ricci, Chiara, pluchino, dario, Scribano, Maria Lia, Bertani, Lorenzo, Sablich, Renato, Pastorelli, Luca, Manguso, Francesco, Variola, Angela, Di Sario, Antonio, Grossi, Laurino, Ribaldone, Davide Giuseppe, Biscaglia, Giuseppe, Buda, Andrea, Balestrieri, Paola, Mocci, Giammarco, Viscido, Angelo, Di Paolo, Maria Carla, Onali, Sara, Rodino', Stefano, Coletta, Marina, Principi, Mariabeatrice, Miranda, Agnese, Amato, Arnaldo, Bezzio, Cristina, Petruzzellis, Carlo, Mazzuoli, Silvia, Festa, Stefano, Sartini, Alessandro, Fanigliulo, Libera, Gallina, Sara, Bodini, Giorgia, Guidi, Luisa, Savarino, Edoardo, Cappello, Maria, Caprioli, Flavio, Fries, Walter, Scaldaferri, Franco, Castiglione, Fabiana, Massari, Alessandro, Orlando, Ambrogio, and Armuzzi, Alessandro

Published
2020
Full Text
View/download PDF

32. Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT

Author

Pugliese, Daniela, Privitera, Giuseppe, Crispino, Federica, Mezzina, Nicolò, Pellegrini, Lucienne, Laterza, Lucrezia, Viola, Anna, Soru, Pietro, Scrivo, Barbara, Barberio, Brigida, Ricci, Chiara, pluchino, dario, Scribano, Maria Lia, Bertani, Lorenzo, Sablich, Renato, Pastorelli, Luca, Manguso, Francesco, Variola, Angela, Di Sario, Antonio, Grossi, Laurino, Ribaldone, Davide Giuseppe, Biscaglia, Giuseppe, Buda, Andrea, Balestrieri, Paola, Mocci, Giammarco, Viscido, Angelo, Di Paolo, Maria Carla, Onali, Sara, Rodino', Stefano, Coletta, Marina, Principi, Mariabeatrice, Miranda, Agnese, Amato, Arnaldo, Bezzio, Cristina, Petruzzellis, Carlo, Mazzuoli, Silvia, Festa, Stefano, Sartini, Alessandro, Fanigliulo, Libera, Gallina, Sara, Bodini, Giorgia, Guidi, Luisa, Savarino, Edoardo, Cappello, Maria, Caprioli, Flavio, Fries, Walter, Scaldaferri, Franco, Castiglione, Fabiana, Massari, Alessandro, Orlando, Ambrogio, and Armuzzi, Alessandro

Published
2020
Full Text
View/download PDF

33. Tu1237 - Epidemiology of Diverticular Disease of the Colon: A Preliminary Analysis from the International “Dica” Prospective Study

Author

Tursi, Antonio, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Annunziata, Maria Laura, Bafutto, Mauro, Baldi, Fabio, Danese, Silvio, Dumitrascu, Dan Lucian, Escalante, Ricardo, Faggiani, Roberto, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria G., Lammert, Frank, Latella, Giovanni, Murphy, Maria M., Oliveira, Lucia C., Oliveira, Enio C., Papagrigoriadis, Savvas, Penna, Antonio, Pietrzak, Anna, Poskus, Tomas, Reichert, Matthias, Rodino', Stefano, Regula, Jaroslaw, Vassallo, Roberto, and Walker, Marjorie M.

Published
2018
Full Text
View/download PDF

40. Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.

Author

Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu DL, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Compare D, Nardone G, Camara De Castro Oliveira L, Chaves Oliveira E, Papagrigoriadis S, Pietrzak A, Pontone S, Stundiene I, Pranzo G, Reichert MC, Rodinò S, Regula J, Scaccianoce G, Scaldaferri F, Vassallo R, Zampaletta C, Zullo A, Spaziani E, Bonovas S, Papa A, and Danese S

Subjects
Humans, Male, Middle Aged, Prevalence, Prospective Studies, Treatment Outcome, Colitis complications, Colitis epidemiology, Colitis diagnosis, Diverticulum complications
Abstract

Introduction: We assessed the prevalence and clinical outcomes of segmental colitis associated with diverticulosis (SCAD) in patients with newly diagnosed diverticulosis., Methods: A 3-year international, multicenter, prospective cohort study was conducted involving 2,215 patients., Results: SCAD diagnosis was posed in 44 patients (30 male patients; median age: 64.5 years; prevalence of 1.99%, 95% confidence interval, 1.45%-2.66%). Patients with SCAD types D and B showed worse symptoms, higher fecal calprotectin values, needed more steroids, and reached less likely complete remission., Discussion: Although SCAD generally had a benign outcome, types B and D were associated with more severe symptoms and worse clinical course., (Copyright © 2023 by The American College of Gastroenterology.)

Published
2023
Full Text
View/download PDF

41. Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis.

Author

Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu DL, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Compare D, Nardone G, Camara De Castro Oliveira L, Oliveira EC, Papa A, Papagrigoriadis S, Pietrzak A, Pontone S, Poskus T, Pranzo G, Reichert MC, Rodinò S, Regula J, Scaccianoce G, Scaldaferri F, Vassallo R, Zampaletta C, Zullo A, Spaziani E, Bonovas S, and Danese S

Subjects
Humans, Colonoscopy, Leukocyte L1 Antigen Complex, Prospective Studies, Inflammation diagnosis, Inflammation complications, Diverticulosis, Colonic diagnosis, Diverticulosis, Colonic therapy, Diverticulosis, Colonic complications, Diverticular Diseases complications, Diverticular Diseases diagnosis, Diverticular Diseases therapy, Diverticulum complications
Abstract

Background and Aims: The Diverticular Inflammation and Complication Assessment (DICA) classification and the Combined Overview on Diverticular Assessment (CODA) were found to be effective in predicting the outcomes of Diverticular Disease (DD). We ascertain whether fecal calprotectin (FC) can further aid in improving risk stratification., Methods: A three-year international, multicentre, prospective cohort study was conducted involving 43 Gastroenterology and Endoscopy centres. Survival methods for censored observations were used to estimate the risk of acute diverticulitis (AD) in newly diagnosed DD patients according to basal FC, DICA, and CODA. The net benefit of management strategies based on DICA, CODA and FC in addition to CODA was assessed with decision curve analysis, which incorporates the harms and benefits of using a prognostic model for clinical decisions., Results: At the first diagnosis of diverticulosis/DD, 871 participants underwent FC measurement. FC was associated with the risk of AD at 3 years (HR per each base 10 logarithm increase: 3.29; 95% confidence interval, 2.13-5.10) and showed moderate discrimination (c-statistic: 0.685; 0.614-0.756). DICA and CODA were more accurate predictors of AD than FC. However, FC showed high discrimination capacity to predict AD at 3 months, which was not maintained at longer follow-up times. The decision curve analysis comparing the combination of FC and CODA with CODA alone did not clearly indicate a larger net benefit of one strategy over the other., Conclusions: FC measurement could be used as a complementary tool to assess the immediate risk of AD. In all other cases, treatment strategies based on the CODA score alone should be recommended., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)

Published
2023
Full Text
View/download PDF

42. Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.

Author

Tursi A, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu D, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Nardone G, Camara de Castro Oliveira L, Chaves Oliveira E, Papa A, Papagrigoriadis S, Pietrzak A, Pontone S, Poskus T, Pranzo G, Reichert MC, Rodinò S, Regula J, Scaccianoce G, Scaldaferri F, Vassallo R, Zampaletta C, Zullo A, Piovani D, Bonovas S, and Danese S

Subjects
Cohort Studies, Colonoscopy, Humans, Inflammation complications, Prognosis, Prospective Studies, Diverticular Diseases diagnosis, Diverticulitis complications, Diverticulitis diagnosis, Diverticulosis, Colonic diagnosis, Diverticulum complications
Abstract

Objective: To investigate the predictive value of the Diverticular Inflammation and Complication Assessment (DICA) classification and to develop and validate a combined endoscopic-clinical score predicting clinical outcomes of diverticulosis, named Combined Overview on Diverticular Assessment (CODA)., Design: A multicentre, prospective, international cohort study., Setting: 43 gastroenterology and endoscopy centres located in Europe and South America., Participants: 2215 patients (2198 completing the study) at the first diagnosis of diverticulosis/diverticular disease were enrolled. Patients were scored according to DICA classifications., Interventions: A 3-year follow-up was performed., Main Outcome Measures: To predict the acute diverticulitis and the surgery according to DICA classification. Survival methods for censored observation were used to develop and validate a novel combined endoscopic-clinical score for predicting diverticulitis and surgery (CODA score)., Results: The 3-year cumulative probability of diverticulitis and surgery was of 3.3% (95% CI 2.5% to 4.5%) in DICA 1, 11.6% (95% CI 9.2% to 14.5%) in DICA 2 and 22.0% (95% CI 17.2% to 28.0%) in DICA 3 (p<0.001), and 0.15% (95% CI 0.04% to 0.59%) in DICA 1, 3.0% (95% CI 1.9% to 4.7%) in DICA 2 and 11.0% (95% CI 7.5% to 16.0%) in DICA 3 (p<0.001), respectively. The 3-year cumulative probability of diverticulitis and surgery was ≤4%, and ≤0.7% in CODA A; <10% and <2.5% in CODA B; >10% and >2.5% in CODA C, respectively. The CODA score showed optimal discrimination capacity in predicting the risk of surgery in the development (c-statistic: 0.829; 95% CI 0.811 to 0.846) and validation cohort (c-statistic: 0.943; 95% CI 0.905 to 0.981)., Conclusions: DICA classification has a significant role in predicting the risk of diverticulitis and surgery in patients with diverticulosis, which is significantly enhanced by the CODA score., Trial Registration Number: NCT02758860., Competing Interests: Competing interests: SD served as speaker, consultant and/or advisory board member for AbbVie, Allergan, Alfa Wassermann, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Johnson and Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, UCB Pharma, Vifor. GM served as speaker and/or advisory board fees for AlfaSigma, Arena, Janssen, Gilead, Roche. GN received funding for target projects from Apharm and Sofar. APserved as lecturer for AlfaSigma and Polpharma. JR served as lecturer for AlfaSigma, Takeda, Ipsen and Servier. FS served as lecturer for Sanofi., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results